Brent Saunders, Bausch + Lomb CEO (Richard Drew/AP Images)
August 3, 2023 09:44 AM EDT
Deals

Bausch + Lomb CEO Brent Saun­ders search­es for small­er deals while 'di­gest­ing' $1.75B Xi­idra move

Andrew Dunn

Senior Biopharma Correspondent

In his sec­ond stint as CEO of Bausch + Lomb, Brent Saun­ders has stayed true to his deal­mak­ing rep­u­ta­tion.

Just a few months af­ter

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times